Understanding how Hodgkin lymphoma cells evade the immune system
Official title: Analysis and Therapeutic Targeting of the Linear-Ubiquitination Pathway in Hodgkin Lymphoma
Funded at Research Inst of Fox Chase Can Ctr · NIH-11097159 · Data updated 2026-11-12
This study is looking at how Hodgkin lymphoma cells manage to hide from the immune system and keep growing, focusing on a specific protein complex, and it aims to find new ways to improve treatments for patients dealing with advanced or returning cases of this cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Research Inst of Fox Chase Can Ctr NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project start | June 1, 2021 |
| Project end | May 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $427,763 |
| NIH project number | 5R01CA251674-05 |
| Project ID | NIH-11097159 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with Hodgkin lymphoma, particularly those with advanced or relapsed disease.
✕Less likely to help
Patients with early-stage Hodgkin lymphoma or those who have not experienced relapse may not benefit directly from this research.
What this research studies
This research investigates the mechanisms by which Hodgkin lymphoma (HL) cells survive and evade the immune system, particularly focusing on a protein complex called LUBAC. Using advanced techniques like CRISPR screening, the study aims to uncover how these cancer cells escape immune detection and continue to thrive despite treatment. By identifying the molecular pathways involved, the research seeks to develop new therapeutic strategies that could improve outcomes for patients with advanced or relapsed HL. The ultimate goal is to enhance the effectiveness of existing treatments and potentially lead to the discovery of novel therapies.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options and higher survival rates for patients with Hodgkin lymphoma.
How similar studies have gone: Other research has shown promise in targeting immune evasion mechanisms in various cancers, suggesting that this approach could be effective for Hodgkin lymphoma as well.
Where this research is happening
-
Research Inst of Fox Chase Can Ctr
Philadelphia, United States Active
Researchers
- Principal investigator: Yang, Yibin — Research Inst of Fox Chase Can Ctr
- Study coordinator: Yang, Yibin
Related research
Other NIH-funded projects on the same topics.
-
Understanding why Black and Hispanic Hodgkin lymphoma patients have worse survival
A patient-centered study to uncover social and care factors that contribute to lower survival among Black and Hispanic people with Hodgkin lymphoma across all ages.
-
Novel combination therapy for non-Hodgkin lymphoma in people and dogs
A new treatment combo using an oncolytic virus and other therapies is being tested to help people with hard-to-treat non-Hodgkin lymphoma, with studies also involving dogs to better understand responses.
-
Trajectories of Neurotoxicity in young Hodgkin lymphoma patients
Aging Hodgkin lymphoma patients who are adolescents or young adults may face long-lasting brain and nerve-related side effects from their cancer treatment, and this study aims to map how those problems develop over time.
-
Combination therapy approach for non-Hodgkin lymphoma (NHL)
A Mayo Clinic team is testing a new combination treatment for non-Hodgkin lymphoma to improve responses in patients and in dogs with similar disease.
-
Multi-antigen T cell therapy for relapsed NHL
A patient-derived T cell therapy called MT-601 targets six tumor-associated antigens to help treat relapsed non-Hodgkin lymphoma after other therapies may have failed.
-
Personalized de‑intensification of therapy for NLP Hodgkin lymphoma
A clinician-scientist at Stanford is developing a patient-centered program to tailor and reduce therapy for nodular lymphocyte-predominant Hodgkin lymphoma using tumor and blood samples.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.